Subtype
Digestive System Adenocarcinoma
CI-CAN-00002525Explore in graph →
1,374 active trials24 approved drugs77 evidence items
- NCIt
- C210140
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002525Explore in graph →
Clinical trials
5,072 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (619)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03990103 | S1+ Paclitaxel (IV&IP) + Bevacizumab (IP) Versus S1+Oxaliplatin as First-line Treatment in Gastric Cancer With Malignant Ascites | unknown | Phase 2 | 66 | China Medical University, ChinaOTHER | 1 | Jun 19, 2019 | clinicaltrials |
| NCT01047969 | Avoiding Surgery in Rectal Cancer After Pre-Operative Therapy | unknown | Phase 2 | 99 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT03981848 | Radiomics-based Non-invasive Classifier Research for HCC-related Liver Transplantation | unknown | — | 200 | Zhejiang UniversityOTHER | 0 | Jun 11, 2019 | clinicaltrials |
| NCT03966118 | Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal Adenocarcinoma(AIO-STO-0218) | unknown | Phase 2 | 59 | P. C. Thuss-PatienceOTHER | 1 | Jun 3, 2019 | clinicaltrials |
| NCT03966209 | Safety and Efficacy of PD-1 Inhibitors in Patients With Liver Transplant | unknown | Phase 1 | 20 | Shanghai Zhongshan HospitalOTHER | 1 | May 31, 2019 | clinicaltrials |
| NCT03950102 | SBRT as Bridging Therapy for Hepatocellular Carcinoma Patients on Transplant Waitlist | unknown | N/A | 40 | The University of Hong KongOTHER | 1 | May 28, 2019 | clinicaltrials |
| NCT03880721 | By Developing a Radiomics Model to Predict the Prognosis of Patients With Hepatocellular Carcinoma After Microwave Ablation | unknown | — | 200 | Chinese PLA General HospitalOTHER | 1 | May 24, 2019 | clinicaltrials |
| NCT03138044 | Combined Ipsilateral Liver Lobe Devascularization and Alcohol Treatment of the Large Hepatocellular Carcinoma | unknown | N/A | 12 | The National Ribat UniversityOTHER | 1 | May 14, 2019 | clinicaltrials |
| NCT03634332 | Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC | unknown | Phase 2 | 35 | Pancreatic Cancer Research TeamOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03939845 | A Prospective, Randomized, Multicenter Study of Comparison of TACE Combination With and Without EBRT for Hepatocellular Carcinoma With Portal Vein Tumor Thrombi | unknown | Phase 3 | 180 | Shanghai Zhongshan HospitalOTHER | 1 | May 7, 2019 | clinicaltrials |
| NCT03812770 | Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | unknown | Phase 2 | 150 | Sun Yat-sen UniversityOTHER | 1 | Apr 17, 2019 | clinicaltrials |
| NCT02781012 | Project Survival-Prospective Biomarker Discovery | unknown | — | 436 | Pancreatic Cancer Research TeamOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03914352 | A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic Resection | unknown | N/A | 40 | Cancer Hospital of Guangxi Medical UniversityOTHER | 1 | Apr 16, 2019 | clinicaltrials |
| NCT03899415 | TCR-Redirected T Cells Therapy in Patient With HBV Related HCC | unknown | Phase 1 | 10 | Beijing 302 HospitalOTHER | 1 | Apr 10, 2019 | clinicaltrials |
| NCT03908840 | Open-label Multicenter Phase 1 Study of TBI 302 as Second-Line Therapy in Patients With Hepatocellular Carcinoma | unknown | Phase 1 | 12 | Evolve BiologicsINDUSTRY | 1 | Apr 9, 2019 | clinicaltrials |
| NCT03869151 | Pretreatment Lymphocyte Monocyte Ratio on Outcome HCC Patients | unknown | — | 1 | Amany Aboalenen AminOTHER | 0 | Apr 2, 2019 | clinicaltrials |
| NCT03884179 | Diagnosis of PCL With EUS-FNA and Cross-sectional Imaging - A Report of Accuracy | unknown | — | 58 | Sahlgrenska University HospitalOTHER | 0 | Mar 21, 2019 | clinicaltrials |
| NCT03857815 | Stereotactic Body Radiation Therapy Combined With Anti-PD-1 Antibody in Patients With Hepatocellular Carcinoma | unknown | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT03881501 | Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma | unknown | — | 2 | Huazhong University of Science and TechnologyOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01891539 | Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma(DEBDOX) | unknown | — | 100 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT02007148 | MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric Cancer(MICADO) | unknown | Phase 2 | 51 | International Group of Endovascular OncologyOTHER | 1 | Feb 27, 2019 | clinicaltrials |
| NCT03853928 | Probiotics in the Prevention of Hepatocellular Carcinoma in Cirrhosis | unknown | N/A | 280 | Austral University, ArgentinaOTHER | 0 | Feb 27, 2019 | clinicaltrials |
| NCT02232490 | Liver Cancer Immunotherapy: Placebo-controlled Clinical Trial of Hepcortespenlisimut-L(Hepko-V5) | unknown | Phase 3 | 120 | Immunitor LLCINDUSTRY | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03468244 | Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms | unknown | N/A | 24 | Changhai HospitalOTHER | 1 | Feb 26, 2019 | clinicaltrials |
| NCT03851887 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Stereotactic Body Radiation Therapy (SBRT) in Unresectable Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 33 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03851939 | The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC) | unknown | Phase 2 | 65 | Sun Yat-sen UniversityOTHER | 1 | Feb 22, 2019 | clinicaltrials |
| NCT03734068 | Chemoembolization Using LifePearl Polyethylene Glycol Drug Eluting Microspheres With Doxorubicin in HCC(LIFDOX) | unknown | — | 100 | International Group of Endovascular OncologyOTHER | 1 | Feb 21, 2019 | clinicaltrials |
| NCT03839550 | Combine Apatinib Mesylate With PD-1 Antibody SHR-1210 for HCC With High Risk of Recurrence After Radical Resection | unknown | Phase 2 | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 15, 2019 | clinicaltrials |
| NCT03837301 | Non-exposure Simple Suturing EFTR (NESS-EFTR) With Laparoscopic Sentinel Lymph Node Navigation for EGC (Senorita3-phase 2) | unknown | Phase 2 | 88 | National Cancer Center, KoreaOTHER_GOV | 1 | Feb 12, 2019 | clinicaltrials |
| NCT03313596 | Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC | unknown | Phase 3 | 180 | Huazhong University of Science and TechnologyOTHER | 1 | Feb 4, 2019 | clinicaltrials |
| NCT03614546 | Clinical Trial of Radiotherapy in Treating Primary Hepatocellular Carcinoma | unknown | N/A | 200 | The Third Xiangya Hospital of Central South UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03812783 | HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | unknown | Phase 2 | 100 | Sun Yat-sen UniversityOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT03807947 | Radial Versus Femoral Access for Superselective Embolization of Hepatocellular Carcinoma | unknown | N/A | 74 | Humanitas Clinical and Research CenterOTHER | 1 | Jan 17, 2019 | clinicaltrials |
| NCT03803891 | Endoscopic Full-Thickness Resection In Colon(EFTRICOM) | unknown | — | 65 | Fundació Institut Germans Trias i PujolOTHER | 1 | Jan 15, 2019 | clinicaltrials |
| NCT03793322 | The Application of Indocyanine-Green(ICG) Fluorescence Imaging in Hepatocellular Carcinoma | unknown | Phase 1 | 100 | Zhujiang HospitalOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT03793725 | A Trial of SHR-1210 in Combination With Apatinib in Patients With Unresectable HCC(HZ-T-PD1-APA) | unknown | Phase 2 | 30 | Yanqiao ZhangOTHER | 0 | Jan 4, 2019 | clinicaltrials |
| NCT03116945 | Novel Gallium Imaging in Hepatocellular Carcinoma | unknown | Phase 2 | 18 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03775395 | HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC | unknown | Phase 3 | 250 | Sun Yat-sen UniversityOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT03791268 | General Tissue Response Classification System After Chemotherapy | unknown | — | 200 | West China HospitalOTHER | 1 | Jan 2, 2019 | clinicaltrials |
| NCT03730675 | Irradiation Stent Placement Plus TACE for HCC and PVTT | unknown | N/A | 308 | Zhongda HospitalOTHER | 1 | Dec 21, 2018 | clinicaltrials |
| NCT02759601 | Dose Escalation Trial of Tefinostat for Cancer Associated Inflamation in Hepatocellular Carcinoma (HCC)(CHR-2845) | unknown | Phase 1 / Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Dec 20, 2018 | clinicaltrials |
| NCT03722875 | SHR-1210 Plus Apatinib in Patients With Hepatocellular Carcinoma After Surgery | unknown | N/A | 45 | Shanghai Zhongshan HospitalOTHER | 1 | Dec 19, 2018 | clinicaltrials |
| NCT03777475 | the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma | unknown | N/A | 350 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2018 | clinicaltrials |
| NCT03673423 | Evaluation of the Interobserver Agreement on the Resectability Status of Patients With a Pancreatic Cancer(OBTCPAN) | unknown | — | 138 | Ospedale San RaffaeleOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT03517332 | Circulating Tumor DNA Exposure in Peripheral Blood | unknown | — | 10,000 | Quantgene Inc.INDUSTRY | 2 | Nov 20, 2018 | clinicaltrials |
| NCT02719782 | A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation | unknown | Phase 1 | 10 | Lion TCR Pte. Ltd.INDUSTRY | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03732547 | Study of PolyIC and PD-1 mAb in Subjects With Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 60 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT03739164 | Tampa Associating Microwave Liver Ablation With Portal Vein Ligation for Staged Hepatectomy (TAMLAPS)(TAMLAPS) | unknown | — | 10 | Florida Hospital Tampa Bay DivisionOTHER | 1 | Nov 13, 2018 | clinicaltrials |
| NCT03722628 | The Assesment of MMP-1 Genotypes Polymorphism as a Risk Factor for HCC in Chronic HCV Patients With LC | unknown | — | 200 | Assiut UniversityOTHER | 0 | Oct 29, 2018 | clinicaltrials |
Data updated 23 days agoSource updated Jun 19, 2019source: clinicaltrials